Target-specific Therapy With Pazopanib as Add-on to Vinflunine in Patients With Advanced or Metastatic Urothelial Carcinoma of the Bladder After Failure of Platinum-based Treatment.

Trial Profile

Target-specific Therapy With Pazopanib as Add-on to Vinflunine in Patients With Advanced or Metastatic Urothelial Carcinoma of the Bladder After Failure of Platinum-based Treatment.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2013

At a glance

  • Drugs Pazopanib (Primary) ; Vinflunine (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 19 Oct 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004086).
    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top